PAYS · Paysign, Inc.

Current Thesis

The 2026-05-12 Q1 print removed the binary that defined this name for the prior six weeks, and it removed it to the upside. Revenue $28.0M (+50.8% YoY vs $18.6M), diluted EPS $0.09 against $0.07 consensus, operating profit $6.7M (+167.9% YoY), net income $5.4M (+110.3% YoY). The feared event the Medicare Part D $2,000 OOP cap clipping copay-card demand not only failed to bite, the Patient Affordability segment accelerated to +168% YoY. Management guided FY26 revenue to $106.5–110.5M and adjusted EBITDA $30–33M, targeting 147–150 active patient-affordability programs by Q2. Fundamentally the bear case is dead. The problem is the tape: the stock rose only ~3.2% on a clean beat-and-raise and now trades ~$6.79 (2026-06-05), roughly 23% below the $8.88 52-week high, with two insiders selling into the move. Good news got sold. A momentum book has no entry until price proves it can hold a higher low.

Bull Case

• Patient Affordability revenue +168% YoY in Q1 (reported 2026-05-12) the high-margin, multi-year-recurring growth engine is accelerating, not decelerating; each new pharma program compounds.
• FY26 guide $106.5–110.5M revenue / $30–33M adjusted EBITDA (2026-05-12) implies ~30–35% top-line growth at ~28% EBITDA margin; operating leverage is proven (operating profit +167.9% YoY on +50.8% revenue).
• Program-count target 147–150 active patient-affordability programs by Q2 (2026-05-12 call) a quantified pipeline with a scoreboard, not a hand-wave.
• Cash and equivalents $179.5M as of Q1 (2026-05-12) against a $379.6M market cap, effectively no long-term debt no refinancing overhang, optionality for buybacks or M&A.
• Sell-side thin and constructive: 4 analysts, consensus Strong Buy, average PT ~$8.06 (high $10, low $5). Low coverage means an upgrade/initiation cycle hasn't happened yet fresh-catalyst optionality.
• The Part D cap question is now settled to the bull side, removing the single largest overhang that capped the multiple into the print.

Bear Case

• The market's verdict on a clean beat-and-raise was +3.17% (2026-05-12), and the stock has since faded ~23% from the $8.88 high. When good news can't lift a tape, distribution is the read.
• Insider selling into the move: EVP Operations Joan Herman sold ~$233,729; CLO Robert Strobo also reduced holdings over the trailing six months (2026 Form 4 activity). The people closest to the numbers are trimming.
• Valuation leaves little cushion: trailing P/E ~39.6, forward ~29.5 (2026-06-05) on a micro-cap whose growth is already guided. A Q2 program-add miss against the 147–150 target compresses the multiple quickly.
• Plasma-card concentration persists: CSL, Grifols and Takeda/BioLife dominate that segment per the FY2024 10-K; a single 8-K customer loss is a 15–25% revenue hole, and plasma collection volumes have run soft industry-wide post-2024.
• No catalyst for roughly two months: the next print (Q2, est. early-to-mid August) is outside any actionable window, so the name drifts on flow with no event to re-rate it.
• ~32% of float sat short into the print; the squeeze did not fire on the beat and price is now lower shorts are pressing a winning thesis, not covering.

Setup & Price Structure

Last ~$6.79 (2026-06-05), inside a $3.08–$8.88 52-week range; market cap $379.6M, ~55.9M shares out, average volume ~550K. The structure is a post-earnings fade: the 2026-05-12 beat produced a one-day pop that has fully bled out, leaving price ~23% under the high and grinding the lower half of the post-print range. Trailing P/E ~39.6 / forward ~29.5, beta 0.74. With the catalyst spent and insiders selling, the path of least resistance is sideways-to-down until a base forms. A constructive entry requires a reclaim of the ~$7.50 post-print shelf on expanding volume (>1.5x ADV) and a confirmed higher low neither is present. Below, the $6.20–$6.50 zone separates consolidation from a distribution leg toward the $5.00–$5.50 analyst-low and prior-base region.

Catalyst Calendar (next 30 days)

• None actionable. The defining catalyst (Q1 2026) already printed 2026-05-12. The next scheduled event is the Q2 2026 release, est. ~2026-08-11 (Q1 reported 5/12; the prior-year Q2 cadence was early August) outside the 30-day window.
• Rolling 8-K watch new pharma-program wins (the 147–150 target gives a running scoreboard) and any plasma-customer change; either can gap a micro-cap 15%+ on no notice.
• Form 4 watch continued insider selling confirms the distribution read; a cluster of insider buys near the $6 base would flip it.

What Would Change Our Mind

A daily close reclaiming the ~$7.50 post-print shelf on >1.5x average volume, paired with a confirmed higher low, would convert the accelerating-fundamentals story into an actionable momentum setup the financials already support it; only price confirmation is absent. Conversely, a daily close below the $6.20–$6.50 base confirms the beat-got-sold distribution and opens the $5.00–$5.50 zone. An 8-K landing the 150th active program ahead of plan, or a sell-side initiation/upgrade (coverage is thin enough that one moves the stock), would be the kind of fresh catalyst that justifies a probe ahead of the August print rather than waiting on it.

Correlation Notes

Idiosyncratic micro-cap; beta 0.74 means index beta is a minor driver prints and 8-Ks move it, not SPX. Demand-side correlates: U.S. plasma-collection volumes (CSL, Grifols, Takeda center counts and donor-fee trends) for the plasma-card leg, and specialty-pharma copay-program spend for the affordability leg. The Medicare Part D $2,000 OOP cap (live since 2025-01-01) is the policy variable the Q1 print just defused; renewed legislative noise on copay-assistance accumulator rules is the tail to watch. No meaningful read-through from AI/semis or the rate cycle. Liquidity is the practical constraint ~550K ADV means sizing, not thesis, is the binding limit for any institutional-scale interest.